カスタム抗体市場：タイプ別、サービス別、供給源別、調査分野別、エンドユーザー別、用途別-2024-2030年世界予測

カスタム抗体市場規模は、2023年に7億5,586万米ドルと推定され、2024年には8億7,188万米ドルに達し、CAGR 16.10%で2030年には21億4,990万米ドルに達すると予測されています。

カスタム抗体は、抗原として知られる単一の標的分子に特異的に結合するように設計・製造された特殊なタンパク質です。これらの抗体は、標的分子上のユニークな部位を認識し、高い特異性で結合するようにオーダーメイドされており、研究、診断、治療用途において貴重なツールとなります。抗体のカスタム生産により、研究者は新規またはあまり研究されていない標的に対する特異的試薬を作製したり、市販されていない所望の特性を持つ抗体を作製したりすることができます。世界中で慢性疾患や感染症が多発しているため、新しい診断用抗体や治療用抗体の開発が必要とされています。バイオ製薬企業や学術機関による研究開発への投資が活発化し、カスタム抗体の普及を後押ししています。しかし、抗体作製には複雑な工程が必要でコストがかかり、抗体治療薬に対する厳しい規制要件は市場参入を遅らせ、開発コストを増加させます。さらに、高い特異性と親和性を持つ抗体の作製は依然として困難であり、カスタム抗体アプリケーションの有効性に影響を与えています。しかし、主要企業はAI/MLアルゴリズムとロボット技術の統合を模索し、抗体の発見と設計のプロセスを容易にしています。さらに、より効率的なハイブリドーマ技術や組み換え抗体生産の開発、標的ドラッグデリバリーシステムや画像診断への応用拡大も業界の成長に寄与する可能性があります。

タイプ重篤な疾病状態に取り組むためのモノクローナル抗体の新たなニーズ

モノクローナル抗体は、単一のB細胞クローンによって産生される同一の抗体です。これらの抗体は単一のエピトープに対して非常に特異的であるため、研究、診断、治療、特にがん、自己免疫疾患、感染症の治療において有用です。ポリクローナル抗体は、単一の抗原を標的とする特異性と一貫性から選択され、特定の分子経路を標的とすることが重要な治療において理想的です。ポリクローナル抗体は異なる免疫細胞に由来し、抗原上の複数のエピトープを認識します。このため非常に汎用性が高く、研究用途、特に多種多様なタンパク質の検出や精製に広く用いられています。複数のエピトープを認識し、診断アッセイにおける感度を向上させる能力を持つことから好まれ、研究環境におけるタンパク質の検出や分析において特に有用です。組換え抗体は、組換えDNA技術を用いてin vitroで作製されます。このカテゴリーにはシングルドメイン抗体やフラグメント抗体が含まれます。高度にカスタマイズ可能な性質により、研究用から治療用まで幅広い用途に適しています。ポリクローナル抗体のようなバッチ間のばらつきがなく、高い特異性と再現性が要求される用途に選択され、治療薬や体外診断薬に適しています。

エンドユーザー製薬・バイオテクノロジー企業による医薬品開発・診断への投資拡大

学術・研究機関は、生物学的プロセスや疾病メカニズムに関する新たな知見を得るためにカスタム抗体を必要とする基礎研究や応用研究プロジェクトに多大な投資を行っています。プロテオミクスやゲノミクス研究を含む様々な研究環境で使用できる、高度に特異的でカスタマイズ可能なオプションが好まれています。これらの研究機関は、予算上の制約から、技術サポートと競争力のある価格設定を提供するプロバイダーを重視しています。医薬品開発業務受託機関（CRO）は、製薬会社と研究活動の橋渡し役として、顧客に代わって臨床試験や研究プロジェクトを幅広く実施しています。CROのカスタム抗体に対するニーズは、高い再現性、大量注文、プロジェクトのタイムラインや規制基準を満たすための時間効率にあります。特にCROは、広範な文書化とバリデーションサービスを提供できるベンダーを好みます。病院や診療所では、主に診断目的や個別化医療にカスタム抗体を利用しています。この分野では、診断や患者のモニタリングに使用できる高精度で臨床的に検証された抗体が求められています。臨床試験段階や規制当局の承認プロセスにおいて強固なサポートを提供できるサプライヤーは高く評価されます。製薬会社やバイオテクノロジー企業は、主に創薬や薬剤開発プロセスにおいて、カスタム抗体のニーズの大部分を占めています。これらの企業は、ハイスループット・スクリーニング、治療への応用、臨床試験におけるバイオマーカーとして統合できる抗体を優先しています。これらの企業は、大規模で一貫した品質の製品を、徹底した文書化と規制基準への準拠とともに提供できるベンダーを求めています。

地域別インサイト

米国とカナダを中心とする南北アメリカは、堅実な研究環境で知られ、カスタム抗体の需要に大きく貢献しています。この地域の強力なバイオテクノロジーと製薬部門がこのニーズを後押ししており、学術研究機関と商業研究機関の両方が、治療・診断用途の高品質で特異的な抗体を求めています。米国における最近の特許は、新規のがんバイオマーカーや神経変性疾患に焦点を当てていることを示しており、抗体開発における技術革新が進行中であることを強調しています。欧州連合（EU）諸国は先進的なヘルスケアシステムとバイオテクノロジー研究に対する強力な規制支援を誇り、研究開発を促進する環境を育んでいます。EUには治療薬や診断薬分子に対する厳格な規制が存在し、カスタム抗体の開発に標準化された安全な枠組みを提供しています。最近のEUの投資は、革新的な抗体ソリューションを通じて、感染症対策や自己免疫疾患などの慢性疾患への対応に重点を置いています。APAC地域は市場情勢において極めて重要な地位を占めており、医療インフラを整備し、社会から疎外された人々が診断薬や治療薬にアクセスできるようにするために、政府が資金を提供するイニシアチブがいくつかあります。中国はバイオテクノロジーの革新に注力し、ゲノムとプロテオミクスの研究に政府投資を行っており、高度に専門化された抗体のニーズを生み出しています。日本の確立された製薬業界は精密医療を優先しており、インドの急成長するバイオテクノロジー部門は、コスト効率の高い製造能力と相まって、カスタム抗体の成長にとって極めて重要であることが証明されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはカスタム抗体市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、カスタム抗体市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.カスタム抗体市場の市場規模および予測は？

2.カスタム抗体市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.カスタム抗体市場の技術動向と規制枠組みは？

4.カスタム抗体市場における主要ベンダーの市場シェアは？

5.カスタム抗体市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性感染症の蔓延が世界中で増加
    • 調査、診断、治療にわたるカスタム抗体の応用の拡大
    • 抗体工学と個別化治療における先進技術の採用増加
  • 抑制要因
    • カスタム抗体の開発には多大な時間と労力がかかる
  • 機会
    • 政府と民間セクターは生命科学と臨床調査に戦略的に投資する
    • 抗体治療薬の増加と医薬品パイプラインの拡大
  • 課題
    • 代替抗体の存在
• 市場セグメンテーション分析
  • タイプ：重篤な疾患に対処するためのモノクローナル抗体の新たな必要性
  • エンドユーザー：医薬品・バイオテクノロジー企業による医薬品開発および診断への投資拡大
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 カスタム抗体市場：タイプ別

• モノクローナル抗体
• ポリクローナル抗体
• 組み換え抗体

第7章 カスタム抗体市場：サービス別

• 抗体開発
• 抗体の断片化と標識
• 抗体の生産と精製

第8章 カスタム抗体市場：ソース別

• マウス
• うさぎ

第9章 カスタム抗体市場調査分野別

• 心血管疾患
• 免疫学
• 感染症
• 神経生物学
• 腫瘍学
• 幹細胞

第10章 カスタム抗体市場：エンドユーザー別

• 学術調査機関
• 契約調査機関
• 病院・クリニック
• 製薬・バイオテクノロジー企業

第11章 カスタム抗体市場：用途別

• 調査
• 治療薬

第12章 南北アメリカのカスタム抗体市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のカスタム抗体市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのカスタム抗体市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ダナハー、抗体サプライヤーのアブカムを57億米ドルで買収へ
  • メルク、108億米ドルの買収でmAbを開発へ
  • セルトリオンとジェヌーブが新たな治療用抗体の開発で提携
• 戦略分析と提言

第16章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. CUSTOM ANTIBODY MARKET RESEARCH PROCESS
• FIGURE 2. CUSTOM ANTIBODY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CUSTOM ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. CUSTOM ANTIBODY MARKET DYNAMICS
• FIGURE 7. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 22. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. CUSTOM ANTIBODY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 28. CUSTOM ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CUSTOM ANTIBODY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CUSTOM ANTIBODY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL CUSTOM ANTIBODY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RECOMBINANT ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY FRAGMENTATION & LABELING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY FRAGMENTATION & LABELING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ANTIBODY PRODUCTION & PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MICE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY MICE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RABBIT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RABBIT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY NEUROBIOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY NEUROBIOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY STEM CELLS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL CUSTOM ANTIBODY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 60. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 61. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 62. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 63. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 64. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 73. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 74. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 75. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 76. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 77. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 78. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 86. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 87. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 88. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 89. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 90. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. CANADA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. CANADA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 100. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 101. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 102. CANADA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 103. CANADA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 104. CANADA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 105. CANADA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 106. CANADA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 107. CANADA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. CANADA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 110. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 111. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 112. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 113. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 114. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 122. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 123. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 124. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 125. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 126. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES CUSTOM ANTIBODY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 135. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 138. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 139. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 140. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 149. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 150. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 151. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 152. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 153. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 154. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 161. CHINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 162. CHINA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 163. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 164. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 165. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 166. CHINA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 167. CHINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 168. CHINA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 169. CHINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 170. CHINA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 171. CHINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 172. CHINA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 173. INDIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 174. INDIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 175. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 176. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 177. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 178. INDIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 179. INDIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 180. INDIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 181. INDIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 182. INDIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 183. INDIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 184. INDIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 185. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 186. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 187. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 188. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 189. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 190. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 197. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 198. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 199. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 200. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 201. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 202. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 209. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 212. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 213. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 214. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 221. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 224. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 225. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 226. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 234. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 235. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 236. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 237. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 238. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 249. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 250. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 257. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 258. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 259. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 260. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 261. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 262. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 270. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 271. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 272. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 273. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 274. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 281. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 284. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 285. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 286. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA CUSTOM ANTIBODY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 307. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 308. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 309. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 310. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 311. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 312. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 319. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 320. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 321. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 322. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 323. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 324. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 331. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 332. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 333. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 334. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 335. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 336. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 337. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 338. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 343. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 344. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 345. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 346. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 347. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 348. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 349. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 350. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 351. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 352. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 353. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 354. FRANCE CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 355. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 356. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 357. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 358. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 359. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
• TABLE 360. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
• TABLE 361. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2023 (USD MILLION)
• TABLE 362. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2024-2030 (USD MILLION)
• TABLE 363. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2018-2023 (USD MILLION)
• TABLE 364. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY END USERS, 2024-2030 (USD MILLION)
• TABLE 365. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 366. GERMANY CUSTOM ANTIBODY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 367. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 368. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 369. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2018-2023 (USD MILLION)
• TABLE 370. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY SERVICE, 2024-2030 (USD MILLION)
• TABLE 371. ISRAEL CUSTOM ANTIBODY MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLI

[188 Pages Report] The Custom Antibody Market size was estimated at USD 755.86 million in 2023 and expected to reach USD 871.88 million in 2024, at a CAGR 16.10% to reach USD 2,149.90 million by 2030.

Custom antibodies are specialized proteins designed and produced to bind specifically to a single target molecule, known as an antigen. These antibodies are tailor-made to recognize and bind with high specificity to unique sites on target molecules, making them valuable tools in research, diagnostic, and therapeutic applications. The custom production of antibodies allows researchers to generate specific reagents for novel or less-studied targets or to create antibodies with desired properties that are not available off the shelf. The high prevalence and incidences of chronic and infectious diseases worldwide necessitate the development of novel diagnostic and therapeutic antibodies. Heightened investment in research and development by biopharmaceutical companies and academic institutions boosts the proliferation of custom antibodies. However, the intricate processes involved in custom antibody production can be cost-intensive, and stringent regulatory requirements for antibody therapeutics can delay market entry and increase development costs. Moreover, generating antibodies with high specificity and affinity remains challenging, impacting the effectiveness of custom antibody applications. However, key players are exploring the integration of AI/ML algorithms and robotics technologies to ease the process of antibody discovery and design. Furthermore, the development of more efficient hybridoma technology and recombinant antibody production and expanding applications in targeted drug delivery systems and diagnostic imaging could also benefit the growth of the industry.

Type: Emerging need for monoclonal antibodies to tackle severe disease states

Monoclonal antibodies are identical antibodies produced by a single B-cell clone. These antibodies are highly specific to a single epitope, making them valuable in research, diagnostic, and therapeutic contexts, particularly for the treatment of cancers, autoimmune diseases, and infectious diseases. They are chosen for their specificity and consistency in targeting a single antigen and are ideal in therapeutic contexts where targeting a specific molecular pathway is crucial. Polyclonal antibodies are derived from different immune cells and recognize multiple epitopes on an antigen. This makes them extremely versatile and widely used in research applications, particularly for detecting and purifying a wide variety of proteins. They are preferred for their ability to recognize multiple epitopes, enhancing sensitivity in diagnostic assays, and are particularly valuable in research settings for protein detection and analysis. Recombinant antibodies are engineered in vitro using recombinant DNA technology. This category includes single-domain antibodies and fragment antibodies. Their highly customizable nature makes them suitable for a broad range of applications, from research to therapeutic use. They are selected for applications requiring high specificity and reproducibility without the batch-to-batch variation seen in polyclonal antibodies and are suited for therapeutics and in vitro diagnostics.

End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics

Academic and research institutes significantly invest in basic and applied research projects that require custom antibodies to uncover novel insights into biological processes and disease mechanisms. Their preference leans towards highly specific, customizable options that can be used in various research settings, including proteomics and genomics studies. These entities value providers that offer technical support and competitive pricing due to budget constraints. Contract research organizations (CROs) serve as a bridge between pharmaceutical companies and research activities, conducting a wide array of clinical trials and research projects on behalf of their clients. Their need for custom antibodies revolves around high reproducibility, bulk orders, and time efficiency to meet project timelines and regulatory standards. Notably, CROs prefer vendors that can provide extensive documentation and validation services. Hospitals and clinics primarily utilize custom antibodies for diagnostic purposes and in personalized medicine applications. The demand within this sector is for highly accurate, clinically validated antibodies that can be used in diagnostics and patient monitoring. Suppliers that can offer robust support in clinical trial phases and regulatory approval processes are highly valued. Pharmaceutical and biotechnology companies represent a significant portion of the need for custom antibodies, mainly for drug discovery and development processes. These companies prioritize antibodies that can be integrated into high-throughput screenings, therapeutic applications, and as biomarkers in clinical trials. They seek vendors that are capable of providing large-scale, consistent quality products with thorough documentation and compliance with regulatory standards.

Regional Insights

The Americas, particularly the U.S. and Canada, are known for their robust research environments, contributing significantly to the demand for custom antibodies. The region's strong biotechnology and pharmaceutical sectors drive this need, with both academic and commercial labs seeking high-quality, specific antibodies for therapeutic and diagnostic applications. Recent patents in the U.S. indicate a focus on novel cancer biomarkers and neurodegenerative diseases, highlighting the ongoing innovation in antibody development. European Union (EU) countries boast advanced healthcare systems and strong regulatory support for biotechnology research, fostering a conducive environment for custom antibody development. The presence of stringent regulations for therapeutics and diagnostics molecules in the EU provides a standardized and secure framework for the progression of custom antibodies. Recent EU investments focus on combating infectious diseases and addressing chronic conditions, such as autoimmune disorders, through innovative antibody solutions. The APAC region has emerged as a pivotal landscape in the custom antibody market, supported by several government-funded initiatives to advance the healthcare infrastructure and provide marginalized communities access to diagnostics and therapeutic capabilities. China's focus on biotechnology innovation and government investments in genomics and proteomics research is creating a need for highly specialized antibodies. Japan's well-established pharmaceutical industry prioritizes precision medicine, and India's burgeoning biotechnology sector, coupled with its cost-effective manufacturing capabilities, has proved crucial for the growth of custom antibodies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Custom Antibody Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Custom Antibody Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Custom Antibody Market, highlighting leading vendors and their innovative profiles. These include Abbiotec, Inc., Abcam PLC, ABclonal, Inc., Abgenex Pvt. Ltd., Abnova Corporation, Acrobiosystems Inc., Agilent Technologies, Inc., Alta Bioscience Limited, Bio Basic Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, BioChain Incorporated, Bioklone Biotech Private Limited, BioLegend, Inc. by PerkinElmer, Inc., Biosynth Ltd., Boster Biological Technology, BTL Biotechno Labs Private Limited, Capralogics, Inc., Cell Signaling Technology, Inc., CiteAb Limited, Creative Biolabs, Creative Diagnostics, CSBio (Shanghai) Ltd., Cusabio Technology LLC, Davids Biotechnologie GmbH, Elabscience, evitria AG by Atlas Antibiodies, GenScript Biotech Corporation, Imgenex India Pvt. Ltd., Innovagen AB, Inotiv, Inc., Kaneka Eurogentec S.A., Laboratory Corporation of America Holdings, Merck KGaA, Metabion International AG, MyBiosource, Inc., OriGene Technologies, Inc., Oy Medix Biochemica AB, Pacific Immunology, PhosphoSolutions, ProMab Biotechnologies, Inc., ProSci Incorporated, ProteoGenix SA, RayBiotech Life, Inc., Rockland Immunochemicals, Inc., Sino Biological, Inc., The Antibody Company, Thermo Fisher Scientific, Inc., and YenZym Antibodies, LLC.

Market Segmentation & Coverage

This research report categorizes the Custom Antibody Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibodies

• Service
  • Antibody Development
  • Antibody Fragmentation & Labeling
  • Antibody Production & Purification

• Source
  • Mice
  • Rabbit

• Research Area
  • Cardiovascular Diseases
  • Immunology
  • Infectious Diseases
  • Neurobiology
  • Oncology
  • Stem cells

• End Users
  • Academic & Research Institutes
  • Contract Research Organizations
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies

• Application
  • Research
  • Therapeutics

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Custom Antibody Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Custom Antibody Market?

3. What are the technology trends and regulatory frameworks in the Custom Antibody Market?

4. What is the market share of the leading vendors in the Custom Antibody Market?

5. Which modes and strategic moves are suitable for entering the Custom Antibody Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of chronic infectious disease worldwide
    • 5.1.1.2. Expanding applications of custom antibody across research, diagnostics, and therapeutics
    • 5.1.1.3. Rising adoption of advanced technologies in antibody engineering and personalized therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. Extensive and time consuming to develop custom antibodies
  • 5.1.3. Opportunities
    • 5.1.3.1. Governments and private sector strategically investments in life science and clinical research
    • 5.1.3.2. Increase in therapeutics of antibodies and expansion of drug pipeline
  • 5.1.4. Challenges
    • 5.1.4.1. Presence of alternative antibodies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Emerging need for monoclonal antibodies to tackle severe disease states
  • 5.2.2. End Users: Expanding investments by the pharmaceutical & biotechnology companies in drug development and diagnostics
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Custom Antibody Market, by Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Polyclonal Antibodies
• 6.4. Recombinant Antibodies

7. Custom Antibody Market, by Service

• 7.1. Introduction
• 7.2. Antibody Development
• 7.3. Antibody Fragmentation & Labeling
• 7.4. Antibody Production & Purification

8. Custom Antibody Market, by Source

• 8.1. Introduction
• 8.2. Mice
• 8.3. Rabbit

9. Custom Antibody Market, by Research Area

• 9.1. Introduction
• 9.2. Cardiovascular Diseases
• 9.3. Immunology
• 9.4. Infectious Diseases
• 9.5. Neurobiology
• 9.6. Oncology
• 9.7. Stem cells

10. Custom Antibody Market, by End Users

• 10.1. Introduction
• 10.2. Academic & Research Institutes
• 10.3. Contract Research Organizations
• 10.4. Hospitals & Clinics
• 10.5. Pharmaceutical & Biotechnology Companies

11. Custom Antibody Market, by Application

• 11.1. Introduction
• 11.2. Research
• 11.3. Therapeutics

12. Americas Custom Antibody Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Custom Antibody Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Custom Antibody Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Danaher to Buy Antibody Supplier Abcam for USD 5.7 Billion
  • 15.3.2. Merck to Develop mAb Through USD 10.8 Billion Acquisition
  • 15.3.3. Celltrion and Genuv Partner to Develop Novel Therapeutic Antibodies
• 15.4. Strategy Analysis & Recommendation

16. Competitive Portfolio

• 16.1. Key Company Profiles
• 16.2. Key Product Portfolio